ARDX
Ardelyx, Inc. Health Care Pharmaceutical Preparations Russell 3000
$3.03Close
$740.4MMarket cap
$3.00 – $7.9952-week range
Nov 3, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 3 · weaker than 97% of stocks over 12 months
- Far from its high 62% below its 52-week high
- Distribution down-day volume 1.9× up-day volume over 50 sessions
- Results soon Nov 3, 2026, in 2 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
62%
1wk
down 1.6%
price change
1mo
down 11.4%
price change
12-month return
down 40%
market up 11% ·
its own down 50%
F-score
3 / 9
Weak
Altman Z
-0.07
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
4.4×
price / book
Earnings yield
down 4.7%
EBIT / enterprise value
Cheaper than
21%
of the market · expensive
Revenue growth
up 22%
year on year
EPS growth
—
latest quarter
Sales growth
up 24%
latest quarter · -4 pts
ROE
down 36%
return on equity
Free cash margin
down 11%
-$44.0M FCF
D/E
1.21
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- profitability slipped from last year
- short-term liquidity weakened
- issued more shares
- assets working less efficiently
- profits backed by cash
- reduced long-term debt
- gross margin widened
Repair signals
- Gross margin 84.8% → 90.3%
Trade setup
ATR%
4.3%
$0.13 a day · 2×ATR $2.77
RS
3 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
0.9×
vs 50-day average
Up/down volume
0.53
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 2.7% over the year, from 238m to 244m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Last shock
Aug 7, 2026-18% in one session4.9× volumeon results-24% since
Financials
- Gross 90%
- Net -15%
- Free cash -11%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $7.6M | $10.1M | $52.2M | $124.5M | $333.6M | $407.3M |
| Gross margin | 98% | 90% | 92% | 86% | 85% | 90% |
| Operating income | -$90.8M | -$154.3M | -$63.8M | -$63.3M | -$27.9M | -$41.0M |
| Net income | -$94.3M | -$158.0M | -$67.0M | -$66.0M | -$39.0M | -$62.0M |
| Net margin | -1246% | -1565% | -128% | -53% | -12% | -15% |
| Earnings per share | -$1.05 | -$1.52 | -$0.42 | -$0.30 | -$0.17 | -$0.26 |
| Free cash flow | -$81.8M | -$154.4M | -$70.1M | -$90.1M | -$45.8M | -$44.0M |
| Free cash margin | -1080% | -1529% | -134% | -72% | -14% | -11% |
| Cash | $91.0M | $72.4M | $96.1M | $21.5M | $64.9M | $68.0M |
| Long-term debt | $50.8M | $32.3M | $26.7M | $49.8M | $150.9M | $202.8M |
| Shareholders' equity | $126.1M | $82.6M | $98.3M | $166.8M | $173.3M | $166.9M |
| Shares outstanding | 93.60m | 130.18m | 198.58m | 232.45m | 238.02m | 244.35m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| Apr 30, 2026 | Quarterly ↗ | Mar 31, 2026 | 30d |
| Feb 19, 2026 | Annual ↗ | Dec 31, 2025 | 50d |
| Oct 30, 2025 | Quarterly ↗ | Sep 30, 2025 | 30d |
| Aug 4, 2025 | Quarterly ↗ | Jun 30, 2025 | 35d |
| May 1, 2025 | Quarterly ↗ | Mar 31, 2025 | 31d |
| Feb 20, 2025 | Annual ↗ | Dec 31, 2024 | 51d |
| Oct 31, 2024 | Quarterly ↗ | Sep 30, 2024 | 31d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 22, 2024 | Annual ↗ | Dec 31, 2023 | 53d |
| Oct 31, 2023 | Quarterly ↗ | Sep 30, 2023 | 31d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 17, 2026 | Other events ↗ |
| Aug 6, 2026 | Results · Regulation FD ↗ |
| Jul 2, 2026 | New obligation ↗ |
| Jun 17, 2026 | Director or officer change · Shareholder vote ↗ |
| Apr 30, 2026 | Results · Regulation FD ↗ |
| Feb 19, 2026 | Results · Regulation FD ↗ |
| Jan 8, 2026 | Results · Other events ↗ |
| Dec 17, 2025 | Director or officer change · Other events ↗ |
| Oct 30, 2025 | Results ↗ |
| Oct 14, 2025 | Director or officer change ↗ |
| Aug 4, 2025 | Results · Director or officer change · Charter or bylaws ↗ |
| Jul 3, 2025 | Material agreement ↗ |